EXJADE offers simple and convenient dosing for your patients compared with previous formulations.^1,2

Non-transfusion-dependent thalassaemia

EXJADE FCTs demonstrate higher bioavailability compared to the EXJADE DTs formulation. In case of switching from DTs to FCTs, the dose of the FCTs should be 30% lower than the dose of the DTs, rounded to the nearest whole tablet.

Starting dose¹

• Recommended initial daily dose: 7 mg/kg/day

Recommended doses for non-transfusion-dependent thalassaemia syndromes¹

Dose adjustments¹

• It is recommended that serum ferritin is monitored every month
• If necessary, the dose of EXJADE may be adjusted every 3–6 months based on trends in LIC or serum ferritin

Adjustments based on LIC or serum ferritin¹

Dose adjustments¹

• In patients where LIC was not assessed and serum ferritin is ≤2,000 μg/L, dosing should not exceed 7 mg/kg
• For patients in whom the dose was increased to >7 mg/kg, dose reduction to 7 mg/kg or less is recommended when LIC is <7 mg Fe/g or serum ferritin is ≤2,000 μg/L

*LIC is the preferred method for iron overload determination.

Abbreviations: DT, dispersible tablet; dw, dry weight; FCT, film-coated tablet; ICT, iron chelation therapy; LIC, liver iron concentration.

References

1. EXJADE^® film-coated tablets summary of product characteristics.
2. Taher A, et al. New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, Phase II ECLIPSE study. Am J Hematol 2017;92(5):420–428.